Related Experiment Video
Updated: May 25, 2026
11:10
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
[Systemic amyloidosis associated with IgD-λ multiple myeloma]
Yasuhiro Nagamachi1, Naofumi Yamauchi, Hirohito Muramatsu
1Department of Hematology, Kiyota Hospital.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|January 14, 2012
Summary
This case report details a rare instance of systemic amyloidosis co-occurring with IgD multiple myeloma. Despite aggressive treatment, the patient
Area of Science:
- Hematology
- Oncology
Background:
- Multiple myeloma is a plasma cell malignancy.
- Systemic amyloidosis involves abnormal protein deposition in organs.
Observation:
- A 59-year-old male presented with macroglossia, joint swelling, and peripheral neuropathy.
- Skin biopsy confirmed amyloid deposition.
- Laboratory tests revealed IgD lambda monoclonal protein and Bence-Jones protein.
Findings:
- Diagnosis of IgD multiple myeloma with systemic amyloidosis was established.
- The patient had elevated monoclonal IgD protein and a high percentage of plasma cells in bone marrow.
- Treatment with melphalan, methylprednisolone, dexamethasone, and VAD therapy was ineffective.
Implications:
- The coexistence of IgD multiple myeloma and systemic amyloidosis is exceptionally rare.
- This case highlights the aggressive nature and poor prognosis of this combined condition.
- Further case reports are crucial for understanding and managing this rare entity.
